Analysis of CT signs, radiomic features and clinical characteristics for delta variant COVID-19 patients with different vaccination status
Tóm tắt
To explore the characteristics of peripheral blood, high resolution computed tomography (HRCT) imaging and the radiomics signature (RadScore) in patients infected with delta variant virus under different coronavirus disease (COVID-19) vaccination status.
123 patients with delta variant virus infection collected from November 1, 2021 to March 1, 2022 were analyzed retrospectively. According to COVID-19 vaccination Status, they were divided into three groups: Unvaccinated group, partially vaccinated group and full vaccination group. The peripheral blood, chest HRCT manifestations and RadScore of each group were analyzed and compared.
The mean lymphocyte count 1.22 ± 0.49 × 10^9/L, CT score 7.29 ± 3.48, RadScore 0.75 ± 0.63 in the unvaccinated group; The mean lymphocyte count 1.55 ± 0.70 × 10^9/L, CT score 5.27 ± 2.72, RadScore 1.03 ± 0.46 in the partially vaccinated group; The mean lymphocyte count 1.87 ± 0.70 × 10^9/L, CT score 3.59 ± 3.14, RadScore 1.23 ± 0.29 in the fully vaccinated group. There were significant differences in lymphocyte count, CT score and RadScore among the three groups (all p < 0.05); Compared with the other two groups, the lung lesions in the unvaccinated group were more involved in multiple lobes, of which 26 cases involved the whole lung. Through the analysis of clinical features, pulmonary imaging features and radiomics, we confirmed the positive effect of COVID-19 vaccine on pulmonary inflammatory symptoms and lymphocyte count (immune system) during delta mutant infection.
Tài liệu tham khảo
Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–3. https://doi.org/10.1016/S0140-6736(20)30185-9.
Gulati A, Pomeranz C, Qamar ZPJ, et al. A comprehensive review of manifestations of novel coronaviruses in the context of deadly COVID-19 global pandemic. Am J Med Sci. 2020;360(1):5–34. https://doi.org/10.1016/j.amjms.2020.05.006.
Choudhary J, Dheeman S, Sharma V, et al. Insights of severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic: a current review. Biol Proced Online. 2021;23(1):5. https://doi.org/10.1186/s12575-020-00141-5.
Torjesen I. Covid-19: Delta variant is now UK’s most dominant strain and spreading through schools. BMJ Clin Res. 2021;373:n1445. https://doi.org/10.1136/bmj.n1445.
EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL. Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update-10 June 2021.ECDC: Stockholm; 2021. https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-sars-cov-2-circulation-variants-concern.
Kannan SR, Spratt AN, Cohen AR, et al. Evolutionary analysis of the delta and delta plus variants of the SARS-CoV-2 viruses. J Autoimmun. 2021;124:102715. https://doi.org/10.1016/j.jaut.2021.102715.
Wang Y, Chen R, Hu F, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou China. EClinicalMedicine. 2021;40:101129. https://doi.org/10.1016/j.eclinm.2021.101129.
Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. https://doi.org/10.1016/S1473-3099(20)30831-8.
Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107–19. https://doi.org/10.1016/S1473-3099(21)00127-4.
Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022;399(10321):237–48. https://doi.org/10.1016/S0140-6736(21)02753-7.
Rubin GD, Ryerson CJ, Haramati LB, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner society. Chest. 2020;158(1):106–16. https://doi.org/10.1016/j.chest.2020.04.003.
Lambin P, Leijenaar R, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–62. https://doi.org/10.1038/nrclinonc.2017.141.
Lubner MG, Smith AD, Sandrasegaran K, et al. CT texture analysis: definitions, applications, biologic correlates, and challenges. Radiographics. 2017;37(5):1483–503. https://doi.org/10.1148/rg.2017170056.
Li Z, Zhong Z, Li Y, et al. From community-acquired pneumonia to COVID-19: a deep learning-based method for quantitative analysis of COVID-19 on thick-section CT scans. Eur Radiol. 2020;30(12):6828–37. https://doi.org/10.1007/s00330-020-07042-x.
Liu H, Ren H, Wu Z, et al. CT radiomics facilitates more accurate diagnosis of COVID-19 pneumonia: compared with CO-RADS. J Transl Med. 2021;19(1):29. https://doi.org/10.1186/s12967-020-02692-3.
National Health Commission of the People's Republic of China. Diagnosis and Treatment Protocols of Coronavirus Disease 2019 (trial 8 edition revision). 2021. Available via http://www.nhc.gov.cn/xcs/zhengcwj/202104/7de0b3837c8b4606a0594aeb0105232b.shtml. Accessed 20 May 2022.
Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020;295(1):202–7. https://doi.org/10.1148/radiol.2020200230.
Cheng Z, Qin L, Cao Q, et al. Quantitative computed tomography of the coronavirus disease 2019 (COVID-19) pneumonia. Radiol Infect Dis. 2020;7(2):55–61. https://doi.org/10.1016/j.jrid.2020.04.004.
van Griethuysen J, Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype. Can Res. 2017;77(21):e104–7. https://doi.org/10.1158/0008-5472.CAN-17-0339.
Shu J, Tang Y, Cui J, et al. Clear cell renal cell carcinoma: CT-based radiomics features for the prediction of Fuhrman grade. Eur J Radiol. 2018;109:8–12. https://doi.org/10.1016/j.ejrad.2018.10.005.
Leoni MLG, Lombardelli L, Colombi D, et al. Prediction of 28-day mortality in critically ill patients with COVID-19: development and internal validation of a clinical prediction model. PLoS ONE. 2021;16(7):e0254550. https://doi.org/10.1371/journal.pone.0254550.
Li T, Qiu Z, Zhang L, et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis. 2004;189(4):648–51. https://doi.org/10.1086/381535.
Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541–3. https://doi.org/10.1038/s41423-020-0401-3.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan China. JAMA. 2020;323(11):1061–9. https://doi.org/10.1001/jama.2020.1585.
Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22(4):483–95. https://doi.org/10.1016/S1473-3099(21)00681-2.
Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022;10(6):e798–806. https://doi.org/10.1016/S2214-109X(22)00112-7.
Phan LT, Nguyen TV, Luong QC, et al. Importation and human-to-human transmission of a novel coronavirus in vietnam. N Engl J Med. 2020;382(9):872–4. https://doi.org/10.1056/NEJMc2001272.
Depeursinge A, Foncubierta-Rodriguez A, Van De Ville D, et al. Three-dimensional solid texture analysis in biomedical imaging: review and opportunities. Med Image Anal. 2014;18(1):176–96. https://doi.org/10.1016/j.media.2013.10.005.
Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021;385(10):875–84. https://doi.org/10.1056/NEJMoa2107715.
Vassallo M, Clement N, Lotte L, et al. Prevalence and main clinical characteristics of fully vaccinated patients admitted to hospital for delta variant COVID-19. Front Med. 2022;9:809154. https://doi.org/10.3389/fmed.2022.809154.
Ravindra Naik B, Anil Kumar S, Rachegowda N, et al. Severity of COVID-19 infection using chest computed tomography severity score index among vaccinated and unvaccinated COVID-19-positive healthcare workers: an analytical cross-sectional study. Cureus. 2022;14(2):e22087. https://doi.org/10.7759/cureus.22087.
Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2. https://doi.org/10.1016/S0140-6736(21)01358-1.
Li XN, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 2021;10(1):1751–9. https://doi.org/10.1080/22221751.2021.1969291.